Steven R. Loranger
Known title: DirectorCIK: 0001226924
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Xylem sees broad analyst price target cuts. Several major banks, including Mizuho, Oppenheimer, and Citigroup, recently lowered their price targets for Xylem. While most firms maintained positive ratings, the reduction in targets reflects a more conservative outlook on the stock's near-term value. The company also announced it will participate in upcoming investor conferences to discuss its strategy.
Transaction History
| EW | ▲ Buy | Grant | 3,251 | $0 | 5/8/2026 | View on chart |
| EW | ▲ Buy | Grant | 1,064 | $0 | 5/8/2026 | View on chart |
| EW | ▲ Buy | Grant | 3,528 | $0 | 5/9/2025 | View on chart |
| EW | ▲ Buy | Grant | 1,154 | $0 | 5/9/2025 | View on chart |
| EW | ▲ Buy | Option Exercise | 5,739 | $260K | 2/14/2025 | View on chart |
| EW | ▼ Sell | Open Market | 5,739 | $439K | 2/14/2025 | View on chart |
| EW | ▲ Buy | Grant | 3,055 | $0 | 5/8/2024 | View on chart |
| EW | ▲ Buy | Grant | 999 | $0 | 5/8/2024 | View on chart |
| XYL | ▲ Buy | Grant | 1,580 | $0 | 5/18/2023 | View on chart |
| EW | ▲ Buy | Grant | 2,803 | $0 | 5/12/2023 | View on chart |
| EW | ▲ Buy | Grant | 898 | $0 | 5/12/2023 | View on chart |
| XYL | ▲ Buy | Grant | 1,812 | $0 | 5/12/2022 | View on chart |
| EW | ▲ Buy | Grant | 2,300 | $0 | 5/4/2022 | View on chart |
| EW | ▲ Buy | Grant | 737 | $0 | 5/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death
The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.